Neovasc has announced that the topline results from its COSIRA trial (a multicentre, prospective, randomised, sham-controlled study) indicate that the company’s percutaneous device (Reducer) significantly improves the symptoms and functioning of patients with refractory angina.
BIOTRONIK has announced that the PK Papyrus covered coronary stent system has received CE mark for the treatment of acute coronary artery perforation.
Neovasc Inc. (TSXV: NVC) has reported topline results for its COSIRA trial assessing the efficacy and safety of the Neovasc ReducerTM, a novel percutaneous device for the treatment of refractory angina. The data shows that the Reducer achieved its primary endpoint, significantly improving the symptoms and functioning of patients disabled by previously untreatable refractory angina. The COSIRA trial also confirmed that the Reducer is safe and well-tolerated, with no reports of device-related serious adverse events. The safety and efficacy data from the randomized, controlled COSIRA trial is consistent with results seen in previous non-randomized pilot studies of the Reducer.
Sunil Rao (Duke Clinical Research Institute, Durham, USA) reported—according to the results of SAFE-PCI for Women trial—that an initial strategy of transradial access is reasonable in women undergoing cardiac catheterisation because it is associated with less bleeding or vascular complications than the transfemoral approach “with the recognition that a proportion of patients will require conversion to femoral access”.
According to the SMART-CASE study, which was presented during a first report investigation at TCT last week, a conservative strategy of only performing percutaneous coronary intervention (PCI) in lesions with a diameter stenosis of >70% does not increase the risk of all-cause death, myocardial infarction, or any revascularisation at 12 months compared with an aggressive strategy of performing PCI in lesions with a diameter stenosis of >50%.
Despite high expectations for the commonly used diabetes drug metformin to improve risk factors for heart disease in people without diabetes, few beneficial effects have been found in a randomised trial of patients with established cardiovascular disease, published in The Lancet Diabetes & Endocrinology.
A new way of using blood pressure-lowering medications could prevent more than a fourth of heart attacks and strokes - up to 180,000 a year - while using less medication overall, according to new research from the University of Michigan Health System and the VA Ann Arbor Healthcare System.
Loyola University Medical Center is the only Chicago hospital participating in a landmark clinical trial of an artificial aortic heart valve that does not require open heart surgery.
Therox has released results from its multicentre Investigational Device Exemption (IDE) pilot study of its next-generation system for supersaturated oxygen (SSO2) therapy. The results, which were presented at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium (27 October–1 November, San Francisco, USA), had a 9.6% median infarct size measured at 30 days.
The OPEN II study and data from a series from the Amsterdam Medical Center, which were both presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference last week (27 October–1 November, San Francisco, USA), show that the Self-Apposing stent (Stentys) can be successfully used outside of its current indication of acute myocardial infarction.
Biotronik has announced that it has received the CE mark for its PK Papyrus covered coronary stent for the management of acute coronary artery perforation. According to a company press release, the PK Papyrus provides 58% greater flexibility and a 24% reduced crossing profile than Abbott Vascular’s Jostent Graftmaster.
Biosensors has announced that it has launched a larger version of its Axxess bifurcation drug-eluting stent. The new 4.0x9mm size received the CE mark in September and has been specifically designed for the safe and effective treatment of bifurcation lesions involving large main branch vessels and wide bifurcation angulation. The stent was launched at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium (27 October–1 November, San Francisco, USA).
Biosensors International has announced four- year results from the BioFreedom First in Man study (FIM), which demonstrated similar clinical outcomes between BioFreedomTM, a polymer-free drug-coated stent (DCS), and Boston Scientific s TaxusTM LibertéTM drug-eluting stent (DES), with no evidence of definite and/or probable stent thrombosis. Results were presented by Dr. Ricardo Costa, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil, at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) meeting, sponsored by the Cardiovascular Research Foundation.
According to a new study, aspirating blood clots does not significantly reduce microvascular obstruction or reduce the risk of death in patients with non-ST-elevation myocardial infarction (NSTEMI), when compared to standard percutaneous coronary intervention (PCI) without thrombectomy.
A clinical trial shows that rapidly cooling patients who have suffered ST-elevation myocardial infarction (STEMI, the most serious form of a heart attack) prior to restoring blood flow is safe and feasible. The findings of the CHILL-MI trial were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world s premier educational meeting specializing in interventional cardiovascular medicine.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos